Genelux CORP 8-K filings

Genelux Corporation has entered into a Sales Agreement with TD Cowen to offer and sell up to $100 million of its common stock through an at-the-market offering.

Genelux Corporation announced an updated corporate presentation detailing recent business and strategic developments.

Genelux Corporation announced the pricing of an underwritten public offering of 6.67 million common shares at $3.00 each, aiming to raise $20.0 million for general corporate purposes, including R&D and clinical trials.

Genelux Corporation announced encouraging interim results from two ongoing trials evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung cancer and non-small cell lung cancer.

Genelux Corporation announced the immediate resignation of Dr. Paul Scigalla as Chief Medical Officer and the appointment of Dr. Jason Litten to the role, effective January 2, 2026.

Genelux Corporation announced a reduction in the exercise price of certain employee stock options to $3.33 per share and reported the results of its 2025 Annual Meeting of Stockholders, including the election of two Class III directors and the ratification of its independent auditor.

Genelux Corporation has announced the pricing of a $10.5 million underwritten offering of 3,000,000 shares of its common stock at $3.50 per share.

Genelux Corporation reports promising preliminary data from its Phase 1b/2 clinical trial for Olvi-Vec in small cell lung cancer and provides an update on FDA correspondence regarding its ovarian cancer treatment.

Genelux Corporation has announced the resignation of its Chief Financial Officer, Lourie Zak, and the appointment of Matt Pulisic as her successor, effective January 30, 2025.

Genelux Corporation released a corporate presentation on November 8, 2024, which may be used in future meetings.

Genelux Corporation reports the resignation of Caroline Jewett as Vice President, Head of Quality, effective October 18, 2024.

Genelux Corporation held its 2024 Annual Meeting of Stockholders, electing two Class II Directors and ratifying its independent auditor.

Genelux Corporation has released a new corporate presentation, which may be used by management in future meetings.

Genelux Corporation has partially exercised an underwriter option, issuing 625,000 shares and accompanying warrants, raising approximately $2.35 million in net proceeds.

Genelux Corporation has announced the pricing of a public offering to raise approximately $27.5 million through the sale of common stock and accompanying warrants.

Genelux Corporation has released a new corporate presentation on April 9, 2024, which may be used in future meetings.

Genelux Corporation has released a new corporate presentation, which may be used by management in future meetings.

Genelux Corporation released a corporate presentation on February 5, 2024, which may be used in future meetings.

Genelux Corporation reports a preliminary cash, cash equivalents, and short-term investments balance of approximately $23.2 million as of December 31, 2023, pending finalization of year-end financial procedures.